our Approach

We are pursuing both clinically validated targets and novel mechanisms to deliver our payloads to the target sites. Our proprietary peptide engineering platform enables high-quality optimization of the peptide ligand vectors for their biodistribution, binding affinity and in vivo stability. Such peptide expertise is complemented by our world-class radiopharmaceutical partners, ensuring the translation of our peptide vectors into superior radioligand theranostic agents. Our preferred clinical development candidates are true theranostic pairs powered by 68Ga, 64Cu, 18F and 177Lu, 225Ac for diagnosis and therapy respectively.